Myosin Therapeutics Awarded $3 Million NIH Grant To Advance Clinical Trial for MT-110 in Methamphetamine Use Disorder

UF Startup Myosin Therapeutics, Inc., a biotechnology company developing innovative therapies for cancer and neurological disorders, announced that it has been awarded a $3 million grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH).

This grant will help support the initiation of a Phase 1 clinical trial to assess the safety, tolerability, and pharmacokinetics of MT-110, laying the foundation for MT-110 as a first-in-class treatment option for methamphetamine use disorder (MUD). MUD is a severe and growing public health crisis with no FDA approved treatments. In the United States alone, over 2.5 million people are estimated to have this use disorder. And, unlike opioids, the number of overdose deaths attributed to methamphetamine increased last year.

Read more about Myosin Therapeutics Awarded $3 Million NIH Grant To Advance Clinical Trial for MT-110 in Methamphetamine Use Disorder.